首页 万春医药(usBYSI)-基本信息

万春医药(usBYSI)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:9.47

最高价:9.52

成交量:29977.0

昨收价:9.37

最低价:9.24

最新价:9.34

行情图标
概要信息

中文名称:万春医药


英文名称:Beyondspring Inc


简介:万春医药公司于2014年11月21日在开曼群岛注册成立。该公司是一家处于全球临床阶段的生物制药公司,专注于新型癌症疗法,包括晚期肿瘤免疫药物的研发


电话:1-646-3056387


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 持股信息
  • 领导人信息

万春医药(BeyondSpring)是一家立足中国,结合中美优势资源,开发具有全球商业价值的新药研发公司。万春医药瞄准全球市场的战略规划在行业内深具特色,万春医药是由中国“千人计划”特聘专家黄岚博士创立,公司拥有全球自主知识产权的首个候选药物有二个适应症进入国际多中心III 期临床,在美国、澳大利亚及中国同时开展临床试验。一个I,II期临床正在收入病人,公司还有多个项目即将开始临床试验研究,同时万春也与Fred Hutchinson 建立了深度合作关系。万春医药拥有独特的商业模式:由中美优秀科学家共同组成技术团队,充分利用中国和美国在新药研发上的各自优势,高效率、低成本开发具有全球商业价值并具有自主知识产权的创新型新药,是中国新药研发企业向创新型转变并走向世界舞台的一个里程碑。BeyondSpring是一家处于全球临床阶段的生物制药公司,专注于新型癌症疗法,包括晚期肿瘤免疫药物的研发。在BeyondSpring,公司的使命是利用其癌症治疗的学术及业务能力,采用独有方式来改变癌症治疗的现状。万春医药的主要项目普那布林(Plinabulin)来源于天然化合物,由于所具有的各种生化活性,对多种癌症有治疗潜力。万春医药采用一种新颖的、高度可扩展的商业模式,整合美中优势资源,高效、低成本地实现药物的报批和开发。目前研究领域: 非小细胞肺癌(Non-Small Cell Lung Cancer)——基于晚期非小细胞肺癌I/II期临床试验2期部分振奋人心的结果,在同FDA协商之后,BeyondSpring开始了普那布林与成熟的抗有丝分裂化疗药物多西他赛的单一的、大规模的、全球3期关键性试验。 BeyondSpring已经开始在美国和中国招募患者。 中性粒细胞减少症预防(Neutropenia Prevention)——中性粒细胞减少症即血液中中性粒细胞(白细胞的一种)的浓度异常低。中性粒细胞读数偏低的患者更易遭受细菌感染,危及生命。2016年开始全球II/III期关键性试验。 普那布林 + PD-1单抗(Plinabulin + Nivolumab)——基于普那布林的肿瘤免疫机理,II期数据中延长的缓解持续时间,以及与检查点抑制剂协同功效的非临床数据,BeyondSpring在正在启动普那布林和PD-1单抗联用治疗非小细胞肺癌的Ib/II期研究,以考察安全性和初步生物标志物的疗效读出。目前,UCSD已经获得FDA批准开始这项研究者发起的研究。在多种非临床研究中,普那布林在包括脑瘤以及存在严重未满足医疗需求的Kras突变肿瘤在内的多种癌症模型中展示出抗肿瘤活性。同时万春医药也利用其极具潜力的项目扩展投资,并专注于解决关键未满足需求领域的目标。普那布林(Plinabulin)简介:普那布林是万春医药拥有的,具有全球自主知识产权的创新药,普那布林是一个多靶点药物,他既能通过促进树突性细胞成熟化,激活和肿瘤抗原有关的T细胞,放大免疫作用;又能直接通过激活JNK通道使肿瘤细胞凋亡;还能直接通过抑制肿瘤血流量来饿死肿瘤。普纳布林注射液治疗非小细胞肺癌的国际多中心三期临床现在已经在美国,中国,澳大利亚开始收入病人,从二期临床试验数据上显示,多西他赛单药治疗的中位总生存期为6.7个月,普那布林与多西他赛联用则有11.3个月。OS延长4.6个月,其肿瘤有效率较多西他赛提高近一倍,持续缓解时间(DOR)是12.7月,就多西他赛的DOR有显著延长,有统计学意义,效果非常显著。另外,普纳布林注射液用于预防化疗引起的中性粒细胞减少症的国际多中心二,三期临已经于2016年9月与美国FDA开会启动,FDA已同意开始试验,中国的国际多中心三期临床申请资料已经上报CDE,预计明年会得到批准并开始临床试验。由于能够激活树突状细胞,产生细胞因子,例如IL-1,IL-6,和IL-12, IL-6保护白细胞不被降解。这个机理使普那布林还可用于预防化疗引起的中性粒细胞减少症。这种不同的作用机制使得普纳布林能够与化疗当天施用,而GCSF则须延迟一天给药。二期临床的数据表明,他的效果已达到统计学意义,并减少骨痛等副作用发生。万春医药BeyondSpring(BYSI)上市背后的力量:2007年,黄岚开始介入普那布林的研究,2013年,她组建了立足纽约、圣地亚哥、大连三地的万春药业,以该公司为载体,主要进行普那布林的研发。2014年开始,仙瞳资本领投2000万美元,支持万春Ⅲ期临床的进行。其他投资方,包括复星实业(香港)、华融资产、博润资本,香港Epiphron Capital Fund I, L.P.等国内外著名投资机构共投资3500万美元。

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
SSGA Funds Management Inc 1700 0.01% 1700 -- 2019-07-31
Tanaka Capital Management Inc 49358 0.21% -2185 -4.24% 2019-03-31
BlackRock Institutional Trust Company NA 37895 0.16% 37895 -- 2019-07-31
BlackRock 36684 0.15% 36684 -- 2019-07-31
Charles Schwab Investment Management Inc 22261 0.09% 22261 -- 2019-07-31
Fidelity Management & Research Company 21791 0.09% -84 -0.38% 2019-07-31
Vanguard Group Inc 21209 0.09% 21209 -- 2019-07-31
Geode Capital Management, LLC 16621 0.07% -16201 -49.36% 2019-03-31
Lincoln Investment Advisors Corporation 13000 0.05% 13000 -- 2019-07-31
Northern Trust Investments Inc 11414 0.05% 9265 431.13% 2019-07-31
Analytic Investors, LLC 7628 0.03% 7628 -- 2019-07-31
SEI Investments Management Corp 4400 0.02% 4400 -- 2019-07-31
Voya Investments, LLC 3984 0.02% 3984 -- 2019-07-31
Pacific Life Fund Advisors LLC (PLFA) 3428 0.01% 3428 -- 2019-07-31
Wells Fargo Funds Management LLC 3193 0.01% 3193 -- 2019-07-31
DWS Investment S.A. 2878 0.01% -- -- 2019-07-31
Legal & General Investment Management America Inc 1789 0.01% 1789 -- 2019-07-31
Nationwide Fund Advisors 1707 0.01% 1707 -- 2019-07-31
Fosun International Ltd 240000 1.04% -- -- 2019-03-31
BlackRock Fund Advisors 356181 1.49% 471 0.13% 2019-07-31
MML Investment Advisers, LLC 1626 0.01% 1626 -- 2019-07-31
Tower Research Capital LLC 595 -- 60 11.21% 2019-03-31
BlackRock Asset Management Canada Ltd 1096 -- 1 0.09% 2019-07-31
ProShare Advisors LLC 1158 -- 1158 -- 2019-07-31
Bank of America Corporation -- -- -1703 -100.00% 2019-03-31
UBS Group AG 120 -- 120 -- 2019-03-31
T. Rowe Price 174 -- 174 -- 2019-06-30
Morgan Stanley - Brokerage Accounts -- -- -530 -100.00% 2019-03-31
Susquehanna International Group, LLP -- -- -9575 -100.00% 2018-06-30
Susquehanna Financial Group, LLLP -- -- -9575 -100.00% 2018-06-30
Morgan Stanley & Co Inc 229 -- -150 -39.58% 2018-06-30
Ever Regal Group Ltd. 4620000 20.51% 4620000 -- 2017-12-31
Fairy Eagle Investment Ltd. 4620000 20.51% 4620000 -- 2017-12-31
Rosy Time Holdings Ltd 3990000 17.71% 3990000 -- 2017-12-31
Shenzhen Sangel Capital Management Ltd. Co. 2105494 9.34% 2105494 -- 2017-12-31
Huarong Tianze Investments Ltd. 1374443 6.10% 1374443 -- 2017-12-31
NPBSIPO Liquidating Trust 2112963 -- 2112963 -- 2017-03-08
UBS Securities LLC 1031 -- 143 16.10% 2017-12-31
Element Capital Management LLC 5660 0.02% 5660 -- 2017-06-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Russell 3000 ETF 4293 0.02% -- -- 2019-07-30
iShares Russell 2000 Small-Cap Index Fd 15987 0.07% 15987 -- 2019-06-30
BlackRock Russell 2000 13473 0.06% 13473 -- 2019-06-30
LVIP SSgA Small Cap Index Fund 13000 0.05% 13000 -- 2019-06-30
Vanguard Russell 2000 Index Fund 12967 0.05% 12967 -- 2019-06-30
Tanaka Growth Fund 12890 0.05% -- -- 2019-02-28
Fidelity 10228 0.04% -84 -0.81% 2019-06-30
Vanguard Russell 2000 Growth Index Fund 8026 0.03% 8026 -- 2019-06-30
Wells Fargo Factor Enhanced Sm Cp IdxCIT 7628 0.03% 7628 -- 2019-06-30
Northern Small Cap Index Fund 6273 0.03% 6273 -- 2019-06-30
BlackRock Russell 2500 5555 0.02% 5555 -- 2019-06-30
iShares Russell 2000 Value ETF 4842 0.02% 9 0.19% 2019-07-31
SEI Extended Market Index (SIIT) Fund 4400 0.02% 4400 -- 2019-07-31
Russell 2000 Index Non-Lendable Fund E 20374 0.09% 20374 -- 2019-06-30
iShares Micro-Cap ETF 21066 0.09% -- -- 2019-07-30
Schwab Small Cap Index Fund 22261 0.09% 22261 -- 2019-06-30
iShares Russell 2000 Growth ETF 92211 0.39% -- -- 2019-07-30
iShares Russell 2000 ETF 233693 0.98% 462 0.20% 2019-07-30
Voya Russell Small Cap Index Port 3984 0.02% 3984 -- 2019-06-30
Pacific Select Fund Small-Cap Index 3428 0.01% 3428 -- 2019-06-30
NT Quality SCC US Fund - Lending 3022 0.01% 873 40.62% 2019-06-30
Northern Small Cap Core Fund 2119 0.01% 2119 -- 2019-06-30
iShares US Small Cap ETF (CAD-Hedged) 1094 -- 1094 -- 2019-06-28
State Street Small/Mid Cap Eq Idx Port 1700 0.01% 1700 -- 2019-06-30
iShares Russell 2500 ETF 71 -- 71 -- 2019-06-28
ProShares UltraPro Russell2000 424 -- 424 -- 2019-06-30
ProShares Ultra Russell2000 734 -- 734 -- 2019-06-30
Tanaka Growth 6445 0.03% -- -- 2018-05-31

Stephen John Kilmer Stephen John Kilmer founded Biotuesday Publishing Corp. and Kilmer Lucas, Inc. Mr. Kilmer is President for Kilmer Lucas, Inc., President of Biotuesday Publishing Corp. (a subsidiary of Kilmer Lucas, Inc.), Head-Investors & Media Relations at Ortho Regenerative Technologies, Inc., Investor Relations Contact at BeyondSpring, Inc. and Investor Relations Contact at IntelGenx Technologies Corp. In the past he occupied the position of Investor Relations Contact at Tearlab Corp., VP-Investor Relations & Corporate Communications at TLC Vision Corp., Senior Account Director at Marketwire, Inc. and Senior Account Director at Sysomos Canada GP Holding Ltd.
Ramon W. Mohanlal Ramon W. Mohanlal holds the position of Chief Medical Officer for BeyondSpring, Inc. In the past he held the position of Chief Executive & Medical Officer at BioPremiere, Inc., Chief Medical Officer for Interleukin Genetics, Inc., Medical Director at Vertex Pharmaceuticals, Inc., Clinical Head-Established Oncology Products at Novartis AG, Principal at Pharmacia Corp. and Principal at Glaxo Wellcome Plc. He received a doctorate from the University of Leiden and an MBA from American InterContinental University, Inc.
G. Kenneth Lloyd G. Kenneth Lloyd founded GKOL, Inc. Presently, he is Chief Scientific Officer of BeyondSpring, Inc. Dr. Lloyd is also on the board of Verne Mendel Medical Corp. He previously occupied the position of Chief Scientific Officer & SVP-Research at Nereus Pharmaceuticals, Inc., Chief Scientific Officer at Dalian Wanchun Biotechnology Co. Ltd., Vice Director at Sanofi SA, Assistant Vice President at Wyeth-Ayerst Research, Vice President-Biology & Drug Discovery at Sibia Neurosciences, Inc. and Director at GKOL, Inc. Dr. Lloyd received a doctorate from the University of Toronto and a graduate degree and an undergraduate degree from McGill University.
Gordon Leroy Schooley Gordon Leroy Schooley occupies the position of Chief Regulatory Officer at BeyondSpring, Inc. Dr. Schooley is also Member of Seacology Foundation. In the past Dr. Schooley was President at Advanced Analytics & Informatics LLC, Principal at GlaxoSmithKline Plc, Principal at McGaw Laboratories, VP-Clinical Research & Regulatory Affairs at Alliance Pharmaceutical Corp., Director-Clinical Research at Newport Pharmaceuticals International, Inc., Chief Scientific Officer for SkyePharma Plc, Chief Scientific Officer at Pacira Pharmaceuticals, Inc. (California), Member of Progene Biomedical, Inc. and Principal at The Upjohn Co. He received a doctorate from the University of Michigan and an undergraduate degree from Brigham Young University.
Ramon W. Mohanlal Mr. Richard A. Brand is CFO & Principal Accounting Officer at BeyondSpring, Inc., Chief Financial Officer at Globaloria, LLC and a Member at Global Association of Risk Professionals. Mr. Brand was previously employed as Chief Financial Officer by KenCast, Inc., Chairman & Chief Executive Officer by Point Capital, Inc., Vice President by Andrews Securities LLC, a Managing Director by Yorkville Advisors LLC, and a Managing Director by Caisse des D�0�1�0�8p�0�1�0�7ts Securities, Inc. He received his undergraduate degree from the University of Iowa and an MBA from The University of Chicago.
Patrick Fabbio Patrick Fabbio is Chief Financial Officer, Secretary & Senior VP at Progenics Pharmaceuticals, Inc. Mr. Fabbio is also on the board of BeyondSpring, Inc. Mr. Fabbio previously was Chief Financial Officer at electroCore, Inc., Chief Financial Officer for Ikano Therapeutics, Inc., Vice President-Finance for Catalent Pharma Solutions, Inc., Vice President-Finance of NPS Pharmaceuticals, Inc., Auditor at Coopers & Lybrand (London) and Controller of Biomatrix, Inc. Mr. Fabbio received an undergraduate degree from Pace University and a graduate degree from New York University.
Quan Qi Song Currently, Quan Qi Song is Managing Director at Henan Zhiyi Investment Co. Development Ltd., President at Shanghai Boning Financial Adviser Co. Ltd. and President & Director at Henan Wanguo Advisory Development Co. Ltd. Dr. Song is also on the board of Hennan Joyline & Joysun Pharmaceutical Stock Co. Ltd., Zhengzhou Bofeng Investment Management Co. Ltd. and BeyondSpring, Inc. He received a doctorate from Renmin University of China and an undergraduate degree from Henan University.
Richard J. Daly Currently, Richard J. Daly occupies the position of Chief Operating Officer at BeyondSpring, Inc. He is also on the board of Catalyst Pharmaceuticals, Inc., Opiant Pharmaceuticals, Inc. and Andean Health & Development. He previously was Chairman, President, Chief Executive Officer & CFO at Neuralstem, Inc., Vice President-Commercial Strategy at TAP Pharmaceutical Products, Inc., Director & Partner at Sagepath Partners LLC, Managing Director at Ravine Rock Partners LLC, President of AstraZeneca LP and Senior Director-Marketing at Takeda Pharmaceuticals U.S.A., Inc. He received an undergraduate degree from the University of Notre Dame and an MBA from Kellogg School of Management.
Lan Huang Founder of BeyondSpring, Inc., Wuxi Mtlh Biotechnology Co. Ltd. and Paramax International, Inc., Lan Huang is an entrepreneur who is Chairman & Chief Executive Officer at BeyondSpring, Inc. and Chief Executive Officer at Wuxi Mtlh Biotechnology Co. Ltd. In the past Dr. Huang held the position of Chief Risk Officer of Paramax International, Inc. Dr. Huang received an undergraduate degree from Lawrence University and a doctorate from the University of California, Berkeley.
G. Kenneth Lloyd G. Kenneth Lloyd founded GKOL, Inc. Presently, he is Chief Scientific Officer of BeyondSpring, Inc. Dr. Lloyd is also on the board of Verne Mendel Medical Corp. He previously occupied the position of Chief Scientific Officer & SVP-Research at Nereus Pharmaceuticals, Inc., Chief Scientific Officer at Dalian Wanchun Biotechnology Co. Ltd., Vice Director at Sanofi SA, Assistant Vice President at Wyeth-Ayerst Research, Vice President-Biology & Drug Discovery at Sibia Neurosciences, Inc. and Director at GKOL, Inc. Dr. Lloyd received a doctorate from the University of Toronto and a graduate degree and an undergraduate degree from McGill University.
Matthew Kirkby Matthew Kirkby is on the board of BeyondSpring, Inc. In the past Mr. Kirkby was Head-Corporate Banking Asia Pacific at The HongKong & Shanghai Banking Corp. Ltd., Head-Global Banking Asia Pacific at NatWest Markets Plc, CEO-North Asia & Co-Head-Investment at CIMB Bank Bhd. (Hong Kong Branch) and MD & Head-Global Banking Asia Pacific at Royal Bank of Scotland Group Plc. He received a graduate degree from Pembroke College Oxford.
Matthew Kirkby Matthew Kirkby is on the board of BeyondSpring, Inc. In the past Mr. Kirkby was Head-Corporate Banking Asia Pacific at The HongKong & Shanghai Banking Corp. Ltd., Head-Global Banking Asia Pacific at NatWest Markets Plc, CEO-North Asia & Co-Head-Investment at CIMB Bank Bhd. (Hong Kong Branch) and MD & Head-Global Banking Asia Pacific at Royal Bank of Scotland Group Plc. He received a graduate degree from Pembroke College Oxford.
Yanbin Xie Founder of BeijingWits Medical Consulting Ltd., Yanbin Xie presently is currently General Manager at this company. Dr. Xie is also on the board of BeyondSpring, Inc. and Beijing Wits Science & Technology Co., Ltd. He received a doctorate from Shanxi Medical University.
Christine Ying Zhao Currently, Christine Ying Zhao occupies the position of Independent Director at BeyondSpring, Inc. Ms. Zhao is also on the board of The Chinese Finance Association. In her past career Ms. Zhao occupied the position of Group Chief Financial Officer at Best Logistics Technologies (China) Co., Ltd. and Managing Director at Merrill Lynch, Pierce, Fenner & Smith, Inc. She received an MBA from Harvard Business School and an undergraduate degree from Fudan University.
Dong Heng Liu Dong Heng Liu is Chief Financial Officer of BeyondSpring, Inc. In his past career he held the position of Executive Director & Partner at Epiphron Capital Ltd. and VP-Investment Banking & Capital Markets at Jefferies Hong Kong Ltd. He received an undergraduate degree from Yale University and an undergraduate degree from Tsinghua University.

量化对比

全部评论 2

  • 【美股盘前消息速报】① 市场关注美联储鲍威尔讲话,期待美国可能出台更多经济支持措施,美股指数期货小幅上涨。截至发稿,道指期货涨0.48%,标普500指数期货涨0.51%、纳指期货涨0.77%;② 欧股普跌,截至发稿,德国DAX30指数、英国富时100指数、法国CAC40指数均跌超1%; ③ 美国4月PPI环比下降1.3%,创2008年12月以来新低;④欧元区3月工业产出环比下降11.3%,创纪录新低,前值为-0.10%;⑤ 吉利德科学宣布与五家仿制药企业达成“买断式授权”,将通过这个渠道为美国以外的127个国家提供瑞德西韦;⑥ 京东盘前涨3.13%,京东持股的达达赴美IPO;⑦ 中概股盘前普涨,万春医药涨5.51%,途牛涨3.71%,跟谁学涨3.43%,拼多多涨2.78%,哔哩哔哩涨2.43%;⑧ 腾讯ADR盘前现涨超4%,第一季度收入超市场预期;⑨ 欧盟将于6月17日前决定是否通过菲亚特克莱斯勒与标致雪铁龙的合并决议。

  • 中概股盘前普涨,万春医药涨5.51%,途牛涨3.71%,跟谁学涨3.43%,京东涨3.31%,拼多多涨2.78%,哔哩哔哩涨2.43%。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐